Watch for Patients on the Parkinson's Med Nourianz
February 2020
Istradefylline (Nourianz, NUR-ee-anz) will be the first NON-dopaminergic "adenosine antagonist" for Parkinson's disease.
It's a once-daily add-on for "off" episodes...when scheduled carbidopa/levodopa wears off between doses and symptoms (rigidity, tremor, etc) return, especially as Parkinson's progresses.
But istradefylline doesn't seem to reduce "off" time more than dopaminergic add-ons...COMT inhibitors (entacapone, etc), dopamine agonists (pramipexole, etc), or MAO-B inhibitors (rasagiline, etc).
Get concise advice on drug therapy, plus unlimited access to CE
Hospital Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote